Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01191775 | A Study of PNT2258 in Patients With Advanced Solid Tumors | completed | Phase 1 | 22 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02552394 | J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts | completed | Phase 1 | 10 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02572284 | Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02833883 | Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | completed | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04839367 | Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)(PROPELLER) | completed | Phase 1 | 30 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT00547339 | Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 94 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | completed | Phase 1 | 17 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04509557 | [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. | completed | Phase 1 | 30 | FutureChemINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02064036 | Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate(CCRO025) | completed | Phase 1 | 17 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT00972309 | A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2022 | clinicaltrials |
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | completed | Phase 1 | 18 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00188695 | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | completed | Phase 1 / Phase 2 | 61 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04470843 | Impact of Acetazolamide in Reducing Referred Postoperative Pain | completed | Phase 1 | 33 | Medical College of WisconsinOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04685811 | Evaluation of PSMA Antagonist Produced by Two Different Methods | completed | Phase 1 / Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT03262103 | Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer | completed | Phase 1 | 13 | Ashutosh Kumar TewariOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02494921 | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | completed | Phase 1 / Phase 2 | 43 | Rahul AggarwalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT01310192 | Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography | completed | Phase 1 | 20 | Queen's Medical CenterOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02012296 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 88 | University of ChicagoOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT02121639 | Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy(ProCAID) | completed | Phase 1 / Phase 2 | 160 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT00779168 | White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02250014 | The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer | completed | Phase 1 | 19 | University of Colorado, DenverOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02653248 | SBRT for Organ Confined Prostate Cancer | completed | Phase 1 | 36 | Northwell HealthOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03412786 | Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases | completed | Phase 1 | 20 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02207504 | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03793543 | Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer | completed | Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT03120832 | Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients | completed | Phase 1 | 12 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT02280317 | Dose Finding Safety Study of VAL201 in Cancer Patients(VAL201-001) | completed | Phase 1 / Phase 2 | 12 | ValiRx PlcINDUSTRY | 0 | Nov 8, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04374240 | A Clinical Trial of AdNRGM Plus CB1954 in Prostate Cancer(AdUP) | completed | Phase 1 | 18 | University of BirminghamOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04574401 | A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy | completed | Phase 1 | 24 | Intuitive SurgicalINDUSTRY | 1 | Oct 22, 2021 | clinicaltrials |
| NCT03136640 | ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 23 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01353625 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | completed | Phase 1 | 118 | CelgeneINDUSTRY | 4 | Oct 5, 2021 | clinicaltrials |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | completed | Phase 1 | 502 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 30, 2021 | clinicaltrials |
| NCT01574937 | XL-184+Abiraterone in Post-Chemo CRPC | completed | Phase 1 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04889651 | A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers | completed | Phase 1 | 40 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Jul 22, 2021 | clinicaltrials |
| NCT01912820 | Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT00916123 | Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer | completed | Phase 1 | 15 | Weill Medical College of Cornell UniversityOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT03481816 | Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 19, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT02125084 | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 | 38 | SCRI Development Innovations, LLCOTHER | 1 | May 4, 2021 | clinicaltrials |
| NCT01868386 | Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate(HypoFX) | completed | Phase 1 / Phase 2 | 32 | Timothy Showalter, MDOTHER | 1 | Apr 28, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2023source: clinicaltrials